The Final Act for Autoimmune Disease
What if autoimmune diseases could be cured with a one-time treatment? At Cabaletta Bio, we believe it is possible.
On a proven foundation of CAR T technology, we are developing innovative and highly specific engineered T cell therapies for patients with B cell-mediated autoimmune diseases, designed to provide deep, durable, and potentially curative responses. Our proprietary Cabaletta Approach to selective B cell Ablation (CABA™) platform is focused on eliminating pathogenic B cells that express autoantibodies, which cause certain autoimmune diseases, while sparing the normal B cells critical to human health. Our CAAR T cell products are designed to target only those abnormal B cells responsible for autoimmune disease – typically fewer than 1% of all B cells – while sparing healthy B cells and preserving normal immunity. We have identified over two dozen B cell-mediated autoimmune diseases where we believe our CABA™ platform may provide a biological opportunity for cure. Our lead candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ trial, which is a Phase 1 study for the treatment of patients with mucosal pemphigus vulgaris (mPV). We have advanced several other high-priority targets into discovery and preclinical testing, including five announced and two unannounced programs.
To harness the immune system through innovative cell and gene therapies to deliver accessible cures for patients.